Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07023835 · ClinicalTrials.gov registry record · Phase 2
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
A Phase 2 study of Amyotrophic Lateral Sclerosis (ALS), sponsored by Zydus Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 17
- Study locations
NCT07023835 is a Phase 2 study of Amyotrophic Lateral Sclerosis (ALS) that is active but no longer recruiting, run by Zydus Therapeutics. The registered enrollment target is 240 participants, roughly in line with the 247-participant average among 17 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target. The trial reports 17 study locations across 14 states.
The verdict
NCT07023835, a Phase 2 study of Amyotrophic Lateral Sclerosis (ALS), is active but no longer recruiting, sponsored by Zydus Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 17
- Study locations
Study Summary
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 50 mg Usnoflast
- DRUG 75 mg Usnoflast
Study Locations (17)
California
- Zydus US015 - La Jolla
- Zydus US008 - Orange
- Zydus US013 - San Francisco
Texas
- Zydus US001 - Dallas
- Zydus US002 - Houston
Connecticut
- Zydus US005 - New Britain
Florida
- Zydus US012 - Tampa
Georgia
- Zydus US007 - Atlanta
Massachusetts
- Zydus US010 - Boston
Michigan
- Zydus US006 - Detroit
Nebraska
- Zydus US014 - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-09-17 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07023835
The ClinicalTrials.gov registry entry for NCT07023835 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 247-participant average among 17 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target. The listed sponsor is Zydus Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis (ALS) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07023835 reports 17 study locations spanning 14 distinct geographic areas - top geographies include California, Texas, Connecticut.
Frequently Asked Questions
What is clinical trial NCT07023835 about?
NCT07023835 is a clinical study titled "Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis". Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
What is the current status of trial NCT07023835?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2025-09-17. Estimated completion is 2028-10.
What conditions does trial NCT07023835 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis (ALS).
What interventions are being tested in trial NCT07023835?
The interventions under investigation include: Placebo (DRUG), 50 mg Usnoflast (DRUG), 75 mg Usnoflast (DRUG).
Who is sponsoring clinical trial NCT07023835?
This trial is sponsored by Zydus Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07023835 being conducted?
This trial has 17 study locations across California, Connecticut, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis (ALS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
RECRUITING · Phase 2
-
Study of COYA 302 for the Treatment of ALS
RECRUITING · Phase 2
-
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
ACTIVE NOT RECRUITING · Phase 2
-
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
COMPLETED · Phase 2
-
Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.